IV期NSCLC原发灶根治性放疗:IASLC共识声明
IASLC晚期放疗技术小组组织国际多学科专家组,基于2010至2025年随机研究证据,评估IV期NSCLC原发肿瘤放疗的作用、时机、剂量、靶区与安全性,重点区分AGA与非AGA人群。在EGFR突变寡转移NSCLC中,III期随机证据支持诱导全身治疗后巩固性早期放疗可延长生存;非AGA人群直接随机证据仍有限。
要点
- EGFR突变寡转移NSCLC:III期随机证据支持诱导全身治疗后早期巩固放疗。
- 非AGA人群:直接随机证据有限,剂量递增可能改善局部区域控制。
- 放疗与全身治疗联合时毒性一般相加,需密切监测不良事件。
核心结论
- IV期NSCLC原发肿瘤根治剂量放疗有日益增多的生物学依据和新出现的试验数据支持,其中EGFR突变人群证据最强。
- 非AGA患者初步发现令人鼓舞,但尚不足以作出确定性治疗推荐。
研究设计与样本
- IASLC晚期放疗技术小组召集国际多学科专家小组,成员包括IASLC多学科临床科学委员会的放疗肿瘤科与内科肿瘤科医生。
- 通过PubMed检索2010至2025年发表的评估转移性NSCLC(AGA与非AGA)原发肺肿瘤放疗的随机研究,并纳入相关已发表和已报告的摘要。
主要发现
- 在EGFR突变寡转移NSCLC中,随机III期证据支持早期给予放疗,表现为诱导全身治疗后的巩固治疗,是一种有前景的延长生存方法。
- 在非AGA人群中,单独分离原发灶照射影响的直接随机证据仍然有限。
- 新出现的随机数据提示,确定性胸部放疗方案的剂量递增可能较低于剂量方案改善局部区域控制。
关键数值与推荐
- 在EGFR突变寡转移NSCLC中,随机III期证据支持诱导全身治疗后早期巩固放疗。
- 新出现的随机数据提示确定性胸部放疗剂量递增可能改善局部区域控制。
- 分次方案应根据原发肿瘤位置个体化,以减轻心肺不良事件。
临床怎么用
- EGFR突变寡转移NSCLC可考虑诱导全身治疗后早期给予巩固性原发灶放疗。
- 非AGA患者原发灶根治剂量放疗需个体化决策,不宜作为确定性推荐。
- 放疗联合全身治疗时应密切监测并记录不良事件,确保不影响全身治疗中断率。
局限性
- 非AGA人群缺乏单独分离原发灶放疗贡献的直接随机证据。
- 最佳靶区仍不确定,豁免受累胸部淋巴结的获益尚未在大规模随机试验中正式研究。
- 数据匮乏,需要前瞻性试验确认原发灶放疗的贡献、安全性及最佳序贯、剂量和靶区。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of radiotherapy (RT) in stage IV NSCLC has traditionally been palliative; however, with advancements in systemic therapies and insights into the evolutionary processes underpinning advanced disease, the rationale for aggressive primary-tumor control has received renewed interest. This International Association for the Study of Lung Cancer (IASLC) consensus statement evaluates the current evidence for the role, timing, dosing, target volumes, and safety of primary-tumor RT in both actionable genomic alterations (AGA) and non-AGA metastatic NSCLC populations. The IASLC Advanced Radiation Technology subcommittee convened a multidisciplinary, international expert panel including radiation oncologists and medical oncologists from the IASLC Multidisciplinary Clinical Sciences Committee. Randomized studies published from 2010 to 2025 evaluating RT to the primary lung tumor in metastatic NSCLC populations (AGA and non-AGA) were identified through PubMed, and relevant published and presented abstracts were included. Evidence was synthesized and discussed to achieve consensus recommendations. In EGFR-mutant oligometastatic NSCLC, randomized phase III evidence supports early delivery of RT, conveyed as consolidation after induction systemic therapy, as a promising life-prolonging approach. In non-AGA populations, direct randomized evidence isolating the impact of primary irradiation remains limited. Emerging randomized data suggest dose escalation of definitive thoracic RT regimens may improve locoregional control compared with lower-dose approaches. Fractionation should be individualized to the primary tumor location to mitigate cardiopulmonary adverse events. Optimal target volumes remain uncertain, and the benefit of excluding involved thoracic lymph nodes has not yet been formally investigated in large, randomized trials. Safety data indicate toxicity is generally additive when RT is integrated with systemic agents; however, careful monitoring and recording of adverse events are important to ensure the addition of RT does not affect systemic therapy discontinuation rates. Definitive-dose RT to the primary lung tumor in metastatic NSCLC is supported by a growing biologic rationale and emerging trial data, with the strongest evidence in EGFR mutant populations. For patients without AGAs, preliminary findings are encouraging but insufficient for definitive treatment recommendations. The paucity of data necessitates prospective trials that isolate the contribution of primary-tumor RT, confirm its safety, and define the optimal RT sequencing, dose, and target volumes.
引用
- McMahon RA, Lee Min Chua K, Faivre-Finn C, et al. Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee. J Thorac Oncol. 2026. PMID: 41934464. doi:10.1016/j.jtho.2026.103643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。